Animal health is at a crossroads, as antibiotics face growing scrutiny and vaccine effectiveness continues to fall short. ADBIOTECH is stepping into that gap with purpose. As a next-generation player in animal immunotherapy, it has developed two breakthrough antibody platforms—IgY and nanobodies—to shift the industry from reactive treatment to proactive prevention. Its IgY technology is already being used to reinforce immunity and enhance vaccine performance in livestock and aquaculture. Meanwhile, its early exploration into nanobodies (single-domain antibodies known for their stability and specificity) points to ADBIOTECH’s frontrunner vision of redefining animal disease control through targeted, immune-based solutions that reduce reliance on antibiotics. In doing so, ADBIOTECH is setting a new standard for addressing animal health challenges globally. The best part is that the antibodies are produced through natural biological processes. IgY is derived from immunizing poultry, collecting their eggs and extracting antibodies from the yolks. It’s administered orally, allowing it to act directly in the gastrointestinal tract, where many infections begin due to pathogen entry through food. The antibodies are especially valuable for offering a noninvasive, targeted response. Nanobodies, on the other hand, are derived from camelids like llamas and alpacas, which naturally produce a unique form of antibody. These are about one-tenth the size of conventional antibodies, penetrating tissues more effectively and delivering precise, injectable treatments. The efficacy lasts 30 days with a single injection, a far more long-acting protection with minimal intervention. “Managing every step in-house, from pure antigen selection to large-scale manufacturing, within our Korea Good Manufacturing Practice-certified facility, we ensure uncompromised oversight across the full development lifecycle, translating scientific rigor into reliable, market-ready solutions,” says Hong Gul Cheong, CEO. ADBIOTECH is continually advancing its nanobody technology to improve efficacy and expand its applications. One such breakthrough is the development of bivalent nanobodies, which link two nanobodies into a single construct. This increases binding strength or enables simultaneous targeting of multiple pathogens. Another innovation is Fc domain binding, where nanobodies are fused with the Fc region of an antibody to extend half-life and enhance immune system engagement. These advances are making a difference in the field, making it possible to prevent diseases such as calf diarrhea, porcine reproductive and respiratory syndrome (PRRS), porcine epidemic diarrhea (PED) and other high-impact conditions affecting livestock health and farm productivity..

M Regenerative Clinic has perfected the balance between cutting-edge innovation and individualized care to deliver regenerative treatments with exceptional speed. With an on-site laboratory directly integrated with its treatment areas, M Regenerative Clinic’s setup allows immediate processing of harvested stem cells. This integration minimizes the time between cell extraction and treatment application, which is critical for preserving cell viability and enhancing therapeutic potential. The clinic’s physicians can adjust the specifics of the therapy based on the patient's health condition and needs. This approach provides personalized medical care that is both effective and responsive to each patient’s unique health circumstances. The clinic ensures every treatment offered is at the pinnacle of current scientific knowledge. Partnering with the Institute of Medical Sciences at the University of Tokyo (IMS), it actively engages in cutting-edge research on stem cells, exosomes and induced pluripotent stem (iPS) cells. “Such alliances empower our clinic with a robust, evidence-based approach, allowing us to provide patients with advanced and effective therapeutic options that extend beyond mere symptomatic relief,” says Dr. Midori Meshitsuka, director..